Valuation : AstraZeneca PLC

Market Cap 24TCr 21TCr 20TCr 18TCr 34TCr 23,29000Cr 34TCr 2,35000Cr 91TCr 11,86500Cr 92TCr 90TCr 37,58900Cr P/E 2026 *
20.3x
P/E 2027 * 17.7x
Enterprise Value 26TCr 23TCr 21TCr 20TCr 36TCr 25,14100Cr 37TCr 2,53700Cr 98TCr 12,80800Cr 99TCr 97TCr 40,57600Cr EV / Sales 2026 *
4.17x
EV / Sales 2027 * 3.83x
Free-Float
96.63%
Yield 2026 *
2.12%
Yield 2027 * 2.26%
Manager TitleAgeSince
Chief Executive Officer 66 01/10/2012
Director of Finance/CFO 52 01/08/2021
Compliance Officer - 01/01/2023
Director TitleAgeSince
Director/Board Member 70 06/04/1999
Director/Board Member 66 01/10/2012
Director/Board Member 65 27/04/2017
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 24TCr
+0.61%-2.62%+49.65%+89.61% 1,00200Cr
-0.04%-4.28%+51.61%+63.85% 64TCr
+0.52%-3.05%+19.20%+69.27% 44TCr
-0.56%-2.92%+30.06%+36.31% 34TCr
+0.65%-14.44%+11.53%+27.23% 26TCr
+1.14%-3.26%-1.38%+11.88% 24TCr
-2.11%-13.35%+38.18%+47.04% 21TCr
-0.90%-5.06%-18.47%-58.14% 20TCr
-1.00%-4.66%+25.10%+87.15% 18TCr
Average -0.17%-5.00%+22.83%+41.58% 39.22TCr
Weighted average by Cap. +0.07%-4.24%+32.13%+56.17%

Financials

2026 *2027 *
Net sales 6.33TCr 5.45TCr 5.13TCr 4.67TCr 8.74TCr 6,02300Cr 8.78TCr 61TCr 23TCr 3,06900Cr 24TCr 23TCr 9,72100Cr 6.69TCr 5.76TCr 5.42TCr 4.94TCr 9.24TCr 6,36600Cr 9.28TCr 64TCr 25TCr 3,24300Cr 25TCr 25TCr 10,27400Cr
Net income 1.2TCr 1.03TCr 974.41Cr 887.85Cr 1.66TCr 1,14400Cr 1.67TCr 12TCr 4.46TCr 58TCr 4.52TCr 4.42TCr 1,84700Cr 1.38TCr 1.18TCr 1.12TCr 1.02TCr 1.9TCr 1,31000Cr 1.91TCr 13TCr 5.11TCr 67TCr 5.17TCr 5.06TCr 2,11400Cr
Net Debt 1.95TCr 1.67TCr 1.58TCr 1.44TCr 2.69TCr 1,85100Cr 2.7TCr 19TCr 7.22TCr 94TCr 7.3TCr 7.14TCr 2,98700Cr 1.18TCr 1.01TCr 953.34Cr 868.65Cr 1.63TCr 1,12000Cr 1.63TCr 11TCr 4.37TCr 57TCr 4.42TCr 4.32TCr 1,80700Cr
Logo AstraZeneca PLC
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (99.8%). Net sales break down by treatment area between oncology (42.6%), cardiovascular, renal and metabolic diseases (23%), respiratory and autoimmune diseases (14.7%), and other (19.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (0.2). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (22.9%), the United States (40.8%), Americas (6.1%) and Africa/Asia/Australia (22.8%).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
25
Last Close Price
157.80USD
Average target price
212.20USD
Spread / Average Target
+34.47%

Quarterly revenue - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!